A strong dose of AI and NLP
Following a rigorous procurement process in which 20 potential solution providers participated, the pharma major selected Genpact and two other companies to go to the next stage. By comparing the competitors’ software solutions against one another, the pharma company wanted to see which had the fastest and most effective machine learning. And which solution would demonstrate the most accurate, automated AE data extraction and coding.
After evaluating the results, the pharma company chose Cora PharmacoVigilance, built on Genpact Cora, an AI-based platform that accelerates digital transformation. The pharma major is using the solution to process cases by reading text, understanding human speech, extracting and codifying AE data, and learning continuously. Cora PharmacoVigilance has a configurable, risk-based approach to automatically extract and code AE data. And it can process most AE cases end-to-end without intervention. When people do need to review the data, it efficiently guides users through the fields most likely in need of changes, streamlining quality control in the process.
What’s more, the AI engine at the heart of Cora PharmacoVigilance learns as users’ correct case data—and that improves accuracy over time. It’s a holistic and integrated SaaS solution that covers everything from source document acquisition to medical review, distribution, and submission as well as aggregate reporting and signal management. It’s even designed to replace legacy case-processing systems—and cut IT costs.
And as the technology learns it will also bring the life sciences giant greater predictive capabilities. By sensing previously undetectable signals and spotting patterns on the fly, it will be able to foresee potential safety issues, which shifts pharmacovigilance from monitoring and reacting, to preventing and protecting.